Integra LifeSciences Q2 Adj EPS Rises to 56c, Beating Q1's 54c
Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Medical Device Stocks · Healthcare
Sentiment
Positive
Importance
7
Price
$19.82
Mkt Cap
$1.537B
52W Low
$8.7
52W High
$20.49
52W Position
128% above low
Off High
3.3% below high
Rel. Volume
1.1× avg
Market data snapshot near publication time
IART has more than doubled off its 52-week low of $8.7.
Summary
Integra LifeSciences reported Q2 adjusted EPS of 56 cents, up from 54 cents in Q1, topping estimates. Q2 revenue slightly beat expectations. This continues the positive earnings trend following the raised full-year guidance in May. The stock is trading near its 52-week high, reflecting improving fundamentals.
At the time of this announcement, IART was trading at $19.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $8.70 to $20.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.
Price Chart
IART - Latest Insights
IART
Jul 29, 2026, 6:15 AM EDT
Price at Filing:
$19.82
Real-time Price:
$19.82
Change:
$0 (0%)
Market Cap:
$1.537B
IART
May 29, 2026, 3:14 AM EDT
Price at Filing:
$16.46
Real-time Price:
$19.82
Change:
+$3.36 (+20%)
Market Cap:
$1.537B
IART
May 08, 2026, 4:15 PM EDT
Price at Filing:
$13.92
Real-time Price:
$19.82
Change:
+$5.90 (+42%)
Market Cap:
$1.537B
IART
May 05, 2026, 4:03 PM EDT
Price at Filing:
$13.23
Real-time Price:
$19.82
Change:
+$6.59 (+50%)
Market Cap:
$1.537B
IART
May 05, 2026, 6:20 AM EDT
Price at Filing:
$10.65
Real-time Price:
$19.82
Change:
+$9.17 (+86%)
Market Cap:
$1.537B